B Degrader Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation.

United statesUnited kingdomPeter kelleherGreg dearbornAdam silversteinKarin hellsvikAdrian gottschalkB degrader programKey recent program updatesAmerican association for cancer researchExchange commissionDegrader programTherapeutics incFoghorn therapeutics incDevelopment expensesCompany annual report on form